Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    STOP-PEDS Pilot: Study to evaluate treatment of pulmonary exacerbations in children 6-18 years old with CF (STOP-PEDS 2.0) , protocol number STOP-PEDS 2.0 NCT04608019

    This study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.

    • Age:

      6 Years to 18 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      50% or greater

    • Number of Visits:

      3

    • Length of Participation:

      18 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients 6 years and older and F/MF genotypes , protocol number VX20-445-119 NCT04545515

    A Phase 3b Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

    • Age:

      Minimum 6 Years

    • Mutation(s):

      F508

    • FEV1% Predicted:

      not specified

    • Number of Visits:

      not specified

    • Length of Participation:

      not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionRecruiting Location: Australia

    A Study to assess the effect of ELX/TEZ/IVA on glucose tolerance in participants with cystic fibrosis , protocol number VX19-445-117 NCT04599465

    This study will evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.

    • Age:

      Minimum age 12 Years

    • Mutation(s):

      F508del

    • FEV1% Predicted:

      30%

    • Number of Visits:

      Not specified

    • Length of Participation:

      No specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceRecruiting Location: Western Australia

    MRI for investigating airway clearance techniques in adults with cystic fibrosis , protocol number ACTRN12620001159943

    We aim to investigate new techniques in magnetic resonance imaging (MRI) pre and post airway clearance techniques (ACT). Adults with CF will be invited to participate, and to perform their usual ACT (i.e. breathing exercises to clear mucus from their airways) within the MRI under the guidance of an experienced physiotherapist. This will allow for innovative cutting edge imaging to be performed before and after the ACT are performed, to provide information on airway structure and function; specifically in regard to the movement of mucous (sputum) and trapped air, and well as dynamic function of the larger airways.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Queensland

    Measuring antibiotic levels in people with cystic fibrosis taking treatment for mycobacterial lung infection. , protocol number ACTRN12619000948190

    We will test the blood levels of important drugs given to patients with CF with NTM infection and compare to the drug levels in people without cystic fibrosis published in other studies. In this way we can help determine whether the doses we are using are correct or need to be changed. If the doses of antibiotics being used in CF are too low this could lead to new dosing regimens being used in future drug trials.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part A) , protocol number (Vertex VX20-445-111 Part A) NCT04537793

    This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      2 Years to 5 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      53 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: California, USA

    Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B) , protocol number VX20-445-111 PART B NCT04537793

    This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      2 Years to 5 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      9

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor in children (PROMISE Pediatric Cohort) (PROMISE-OB-18 - Pediatric Cohort) , protocol number NCT04613128

    This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.

    • Age:

      6 to 11 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 SAD) , protocol number Armata Phase 1b/2 SAD NCT04596319

    This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      8

    • Length of Participation:

      29 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 MAD) , protocol number Armata Phase 1b/2 MAD NCT04596319

    This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      10

    • Length of Participation:

      31 days

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 211)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|